In the first part of our Trends webinar series, our experts discussed how this shift has facilitated novel collaboration between health systems, plans, and pharmaceutical manufacturers and has also led to many new opportunities–but how is the healthcare landscape responding? Join us to learn how new clinical and scientific innovations are shifting the healthcare paradigm.
Congratulations to PRECISIONheor’s Meaghan Roach MPH, Caroline Huber MPH, Suepattra May-Slater MPH, PhD, and Isha Desai MPH on the successful presentation of their poster “A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States” at NCCN 2021.
Co-hosted by Endpoints Webinars, this panel discussion will address the growing industry concerns regarding manufacturing hurdles unique to cell and gene therapy. Watch as our panel of experts helps set the landscape for the current state of the advanced therapy sector and share key considerations that go into deciding whether to scale-up manufacturing internally or look to an external supplier like a CDMO.
Less than 100 days into a new decade, COVID-19 has revealed fissures and strengths within the healthcare ecosystem, and highlighted opportunities for novel collaborations among health systems, plans, and pharmaceutical manufacturers. Join Precision experts Ross Maclean, Dominic Galante and Maureen Hennessey as they offer insights into trends that are gaining velocity. Watch “Beyond the First 100 Days: Healthcare Policy and Value-Based Care Trends That You Need to Know” on-demand today.
Are you attending the Gene Therapy for Rare Disorders virtual conference this year? Make sure you stop by to check out our booth between February 22-25, and schedule time to chat with our experts!
We are attending PMSA Virtual 2020! Check out our PRECISIONxtract virtual booth to learn more about our proprietary RApid Payer, Provider, & Patient Integrated Data (RAPID) Ecosystem and learn how to connect your data to unlock insights.
This second webinar in our SDOH series will feature KOLs emphasizing applied learnings in the SDOH and population health fields. The session will address collaborative patient engagement: how styles of communication, analytics, telemedicine and PHM are tackling social risks and engaging patients in the pandemic/infodemic era.
Manufacturing has been widely recognized as a bottleneck to bring advanced cell and gene therapies to the patients and families in need. The question is, should organizations stay the course internally, or look externally for their manufacturing needs?
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 – 19 November, 2020.
A deep dive into the future of biosimilars: In this In this exclusive 2-part video interview for AJMC’s Center for Biosimilars, editor Matthew Gavidia speaks with PRECISIONvalue’s Ryan Cox to discuss what employers can do to encourage biosimilar uptake, the cultural changes that are needed to make it happen, and whether midsize employers can participate in payer discussions on formulary placement.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
